[1]谈在祥,蒋雨彤.我国干细胞临床研究与应用的规制及监管研究[J].卫生经济研究,2021,38(7):33-37，43.
　TAN Zai-xiang,JIANG Yu-tong.Research on Regulation and Supervision of Clinical Research and Application of Stem Cell in China[J].Journal Press of Health Economics Research,2021,38(7):33-37，43.
点击复制

我国干细胞临床研究与应用的规制及监管研究
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
38
期数:
2021年7期
页码:
33-37，43
栏目:
聚焦医改
出版日期:
2021-06-30

文章信息/Info

Title:
Research on Regulation and Supervision of Clinical Research and Application of Stem Cell in China
作者:
谈在祥1; 2; 蒋雨彤3
1.徐州医科大学卫生政策与健康管理研究中心, 江苏 徐州 221004
2.徐州医科大学附属医院，江苏 徐州221006
3.徐州医科大学第二临床医学院，江苏 徐州 221006
Author(s):
TAN Zai-xiang;  JIANG Yu-tong
Health Policy and Management Research Center, Xuzhou Medical University, Xuzhou Jiangsu 221004, China
关键词:
干细胞; 临床研究与应用; 规制; 监管
Keywords:
stem cell;  clinical research and application;  regulation;  supervision
分类号:
R19
文献标志码:
A
摘要:
分析了我国干细胞临床研究与应用的现状，认为目前存在立法监管和伦理方面的问题，在介绍国外干细胞临床研究与应用的立法进展基础上，提出促进我国干细胞临床研究与应用发展的建议：专门立法，规范干细胞研究与应用；加强对胚胎来源和干细胞伦理研究的管控；制定符合我国特色的干细胞研究与应用审批监管体系；加大对干细胞研究与应用中的违法行为的惩治力度。
Abstract:
The status of clinical research and application of stem cell in China is analyzed, and it is considered that there are legislative supervision and ethical problems at present. On the basis of introducing the legislative progress of clinical research and application of stem cell abroad, this paper puts forward some suggestions to promote the development of clinical research and application of stem cell in China: special legislation to standardize the research and application of stem cell, and strengthening the management and control of embryonic sources and ethical research of stem cell, formulating a supervision and approval system for research and application of stem cell with Chinese characteristics, and strengthening the punishment of illegal acts in research and application of stem cell.

参考文献/References:

[1] 张健萍，程涛，张孝兵.造血干细胞基因治疗:进展与挑战[J].中国科学：生命科学，2017，47（12）：1323-1335.
[2] 王国梁，梁钏镭，刘红,等.中国干细胞临床备案研究现状[J].云南大学学报（自然科学版），2020，42（S2）：76-91.
[3] 项楠，汪国生，厉小梅.我国干细胞临床研究现状分析、政策回顾及展望[J].中华细胞与干细胞杂志（电子版），2020，10（5）：303-309.
[4] 何萍，程涛，郝莎.干细胞临床研究的现状及展望[J].中国医药生物技术，2020，15（3）：290-294.
[5] Petersen A,Seear K,Munsie M.Therapeutic journeys:the hopeful travails of stem cell tourists[J].Sociology of health & illness,2014,36(5):670-685.
[6] Cyranoski D.China announces stem-cell rules.Nature,2015.
[7] Rosemann A,Sleeboom-Faulkner M.New regulation for clinical stem cell research in China:expected impact and challenges for implementation[J].2016.
[8] Center for drug evaluation,National Medical Products Administration,technical guidance for the research and review of cell therapy products.2017.
[9] 卢加琪，刘伯宁，罗建辉.基于干细胞的再生医学产品研究进展与监管现状[J].中国科学：生命科学，2019，49（1）：18-27.
[10] International Society for Stem Cell Research.Guidelines for stem cell research and clinical translation[J].International Society for Stem Cell Research,2016.
[11] Daley G Q,Hyun I, Apperley J F,et al.Setting global standards for stem cell research and clinical translation:the 2016 ISSCR guidelines[J].Stem cell reports,2016,6(6):787-797.
[12] 孟安明，张思光.干细胞研究中的伦理，法律，社会问题及科学共同体的责任[J].科学与社会，2013，3（1）：54-62.
[13] 李少婷，黄永增，蔡晓珍，等.胚胎干细胞临床试验中的伦理学问题及对策分析[J].中国医学伦理学，2018，31（9）：1162-1165.
[14] 马晨光，薛迪.干细胞研究与应用的伦理问题，伦理规范与伦理实证研究[J].中国医学伦理学，2019，32（1）：26-29.
[15] Zarzeczny A,Scott C,Hyun I, et al. iPS cells:mapping the policy issues[J].Cell,2009,139(6):1032-1037. [16] Moradi S,Mahdizadeh H,?觢ari T,et al.Research and therapy with induced pluripotent stem cells(iPSCs):social,legal,and ethical considerations[J].Stem Cell Research & Therapy,2019,10(1):1-13.
[17] Liu Z,Cai Y,Wang Y,et al.Cloning of macaque monkeys by somatic cell nuclear transfer[J].Cell,2018,172(4):881-887.
[18] 姜天娇，孙金海.国外干细胞产品监管现状及对我国的启示[J].中国社会医学杂志，2016（2）：117-120.
[19] 陈海丹.干细胞临床研究政策回顾和展望[J].自然辩证法通讯，2018（3）：13.
[20] Sharma R.Introductory Chapter:Stem Cells and Tissue Engineering in Medical Practice[J].Stem Cells in Clinical Practice and Tissue Engineering,2018:1.
[21] Witten C M,McFarland R D,Simek S L.Concise review:the US Food and Drug Administration and regenerative medicine[J].Stem cells translational medicine,2015,4(12):1495-1499.
[22] 陈云，邹宜醓，邵蓉，等.美国干细胞产业发展政策与监管及对我国的启示[J].中国医药工业杂志，2018，49（12）：1733.
[23] Rosemann A,Bortz G,Vasen F,et al.Global regulatory developments for clinical stem cell research:diversification and challenges to collaborations[J].Regenerative medicine,2016,11(7):647-657.
[24] Knoepfler P S.From bench to FDA to bedside:US regulatory trends for new stem cell therapies[J].Advanced drug delivery reviews,2015,82:192-196.
[25] 吴曙霞，杨淑娇，吴祖泽.美国，欧盟，日本细胞治疗监管政策研究[J]. 中国医药生物技术，2016，11（6）：491-496.
[26] Salmikangas P,Schuessler-Lenz M,Ruiz S,et al.Marketing regulatory oversight of advanced therapy medicinal products (ATMPs) in Europe:the EMA/CAT perspective[J].Regulatory Aspects of Gene Therapy and Cell Therapy Products,2015:103-130.
[27] MacGregor C,Petersen A, Munsie M.Regulation of unproven stem cell therapies—medicinal product or medical procedure[J]. 2015.
[28] Hyry H I,Manuel J,Cox T M,et al.Compassionate use of orphan drugs[J].Orphanet journal of rare diseases,2015,10(1):1-9.
[29] 高建超.关于我国细胞治疗产业发展现况和监管思路的浅见 （下）[J].中国医药生物技术,2019，14（4）：289-293.
[30] Faulkner A.Opening the gateways to market and adoption of regenerative medicine?The UK case in context[J].Regenerative Medicine,2016,11(3):321-330.
[31] 陈云，邹宜諠，张晓慧，等.韩国与日本干细胞药品审批，监管及对我国的启示[J].中国新药杂志，2018，27（3）：267-272.
[32] Azuma K,Yamanaka S.Recent policies that support clinical application of induced pluripotent stem cell-based regenerative therapies[J].Regenerative Therapy,2016,4:36-47.
[33] Sipp D,Okano H.Japan strengthens regenerative medicine oversight[J].Cell Stem Cell,2018,22(2): 153-156.
[34] Azuma K.Regulatory landscape of regenerative medicine in Japan[J].Current Stem Cell Reports,2015,1(2):118-128.
[35] 李茜.胚胎干细胞研发的法律探讨[J].医学与法学，2018，10（3）： 6-11.
[36] Sipp D,Caulfield T, Kaye J,et al.Marketing of unproven stem cell–based interventions:A call to action[J].Science Translational Medicine,2017,9(397):426.

更新日期/Last Update: 2021-06-30